title: The effect of CagA status on response to Helicobacter pylori eradication therapy in Western Turkey.
abstract: If cytotoxin-associated gene A (CagA) status affects the response rates of therapy, then it may be possible to predict Helicobacter pylori eradication rates. We aimed to evaluate the response to eradication treatment of H. pylori infection in CagA-positive and CagA-negative patients. A total of 184 patients (93 males, 91 females, mean age 42.6 +/- 12.8 years) with H. pylori-positive chronic gastritis were studied. Subjects underwent a gastroscopy and biopsy specimens were taken from the gastric antrum, body, and fundus. Before the eradication therapy was given all patients were tested for CagA, TNF-alpha and gastrin levels. They were then prescribed lansoprazole (30 mg bid), clarithromycin (500 mg bid), and amoxicillin (1.0 mg bid) for one week. On the 8th week a second endoscopy was performed and further biopsy specimens were obtained from the same sites as in the initial endoscopy. One hundred and twenty-seven patients (69.1%) were found to be CagA positive and 57 patients (30.9%) were CagA negative. The total eradication rate was 82.6%. In the CagA-positive group this rate was 87.4%, and in the CagA-negative group it was 71.9% (P = 0.019). TNF-alpha levels were higher in the CagA-positive than in the CagA-negative group (P = 0.001). However, gastrin levels were not different between groups (P = 0.421). Our findings revealed that CagA-negative status might be a risk factor for failure of H. pylori triple therapies. The CagA pathogenicity island gives a growth advantage to H. pylori strains and has been associated with an increase in the inflammatory response at the gastric mucosal level. These properties could make CagA-positive H. pylori strains more susceptible to antibiotics.
authors.affiliation: Department of Gastroenterology, Faculty of Medicine, Celal Bayar University, Manisa, Turkey. msaruc@hotmail.com
authors.forename: M
authors.initials: M
authors.lastname: Saruç
authors.forename: G
authors.initials: G
authors.lastname: Goksel
authors.forename: S
authors.initials: S
authors.lastname: Ozkaya
authors.forename: F
authors.initials: F
authors.lastname: Guclu
authors.forename: B
authors.initials: B
authors.lastname: Ozbakkaloglu
authors.forename: H
authors.initials: H
authors.lastname: Yuceyar
mesh_terms: D000328:Adult; D000942:Antigens, Bacterial / Q000097:blood*; D001426:Bacterial Proteins / Q000097:blood*; D016009:Chi-Square Distribution; D002908:Chronic Disease; D005260:Female; D005756:Gastritis / Q000097:blood / Q000188:drug therapy / Q000382:microbiology*; D016481:Helicobacter Infections / Q000097:blood* / Q000188:drug therapy; D016480:Helicobacter pylori; D006801:Humans; D008297:Male; D008875:Middle Aged; D012307:Risk Factors; D014409:Tumor Necrosis Factor-alpha / Q000032:analysis; D014421:Turkey
chemical_list: D000942:Antigens, Bacterial; D001426:Bacterial Proteins; D014409:Tumor Necrosis Factor-alpha; C080866:cagA protein, Helicobacter pylori